An early investor in recent mega successes such as Revolution Medicines, Peloton, Blueprint Medicines, and Parabilis, he describes his investment philosophy and focus on precision oncology companies. Plus, his early life, getting hands on experience in biotech at Micromet, and learning from some of the top investors and scientific advisors in the industry. Chapters Early life and university - 0:58 Micromet - 11:18 PhD & SiROP - 13:50 Joining Nextech - 19:48 "Character forming

LB2501 is a CD19/CD20 dual targeting CAR-T. He discusses the EHA data, and next steps for the program. Plus, a review of last week's DLL3 data from ASCO and how he thinks about partnering and the competitive landscape.

With M&A news like GSK's $10.6B acquisition of Nuvalent and more positive clinical trial data in the pancreatic cancer space, biotech mostly outperformed the broader market this week.

CEO Richard Paulson walks us through the unmet need in myelofibrosis and the phase three data, which almost doubled the percent of patients achieving SVR35 (a measure of spleen volume reduction) at Week 24, one of the trial's co-primary endpoints. The company will also have a key pivotal trial readout in endometrial cancer sometime in the middle of this year.

He says he believes the Roche deal is an important transaction for the entire field of degraders. Plus, discussing antibody-degrader conjugates and an update on the company's immunology programs as well.

She shares a data update for both, which she believes are as strong as autologous CAR-T, and discusses recent FDA feedback Caribou has received from FDA on the pivotal trial design for the CD19 program in 2L LBCL.

Co-Founders Alex Evans and Alberto Conti talk about winning the golden ticket and how it has already been helping them, and share advice for others who might be interested in applying one day. Plus, general advice for new bio entrepreneurs.

Inspired by the Nobel Prize winning work of Carolyn Bertozzi, Co-Founder and CEO Sophie James describes the science that underlies the company. Plus, moving into Victoria House in London and her advice for other entrepreneurs.

He discusses in vivo CAR-T data from Legend, and how Incyte is planning for the loss of exclusivity on Jakafi. Plus, his take on last week's summit data, and watching out for future catalysts from Ionis and Tyra.

General Manager Simon Williams describes how the liquid biopsy works and what PlaqueTec is doing in its analysis of the samples. The company is current in an approximately 300 person clinical trial that will finish up towards the end of next year.

Co-Founder and CEO Cristiana Pires describes this unique approach, which is in late stage pre-IND work and recently was presented at AACR and ASGCT. The company already has an impressive roster of investors backing it.

Chief Scientific Officer Björn Frendéus walks us through the companies antibody discovery platform, and the two lead clinical assets, which target TNFR2 and FcγRIIB.

Co-Founder and CEO Léa Wenger, who has personally had this condition, describes the company's work and her strong belief that the company must better understand the human biology involved. In that regard, they have a unique program to collect and study menstral blood from donors. Cyclana was recently accepted into Eli Lilly's Virtual Gateway accelerator program.

GSK will pay Engitix approximately $59M up front and up to approximately $157M more in potential milestones. Engitix Co-Founder and CEO Giuseppe Mazza discusses the deal and the company's platform.

He believes that GLPs will always be the backbone of weight loss therapies and points out that they are the only weight loss medicines that have shown a cardiovascular benefit. Plus, why he thinks entrepreneurs in Europe should take a nod from other areas and be more nimble and take more risks in the future.

In New York to ring the open bell in celebration of the listing of the AstraZeneca's ordinary shares on the NYSE earlier this year, he discusses M&A, PD-1 x VEGF, PD-1 x TIGIT, Baxfendy, and the company's efforts in obesity ahead of this weekend's American Diabetes Association Scientific Sessions.

He says the mood overall in biotech is dramatically better than it has been during the previous 2-3 years, and he is unsure about whether the AI factor will continue to attract investors like generalists who have been revisiting the sector.

Co-Founder & CEO Willie Xiang discusses the platform and the company's progress to getting them into the clinic. Current programs target cardiometabolic diseases and solid tumors.

He describes how new technologies will revolutionize biotech, and his hope that more UK companies grow for the long-term rather than being sold to foreign multi-nationals.